Provided is an emulsion composition that is capable of enhancing systemic absorption for various carotenoids, well compatible with soft capsules, and capable of being formulated into a soft capsule formulation, and that homogeneously disperses raw materials including carotenoids and emulsifiers in the soft capsule formulation. An emulsion composition containing a carotenoid, and two or more specific emulsifiers selected from the group consisting of tetraglycerin monooleate, decaglycerin monolaurate, sucrose stearate, and sucrose laurate.

Provided is an emulsion composition that is capable of enhancing systemic absorption for various carotenoids, well compatible with soft capsules, and capable of being formulated into a soft capsule formulation, and that homogeneously disperses raw materials including carotenoids and emulsifiers in the soft capsule formulation. An emulsion composition containing a carotenoid, and two or more specific emulsifiers selected from the group consisting of tetraglycerin monooleate, decaglycerin monolaurate, sucrose stearate, and sucrose laurate.

Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and/or -hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation -hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

Disclosed are compositions enriched with thymohydroquinone, further comprising of thymoquinone, hederagenin and/or -hederin formulated by blending the active molecules isolated from the seeds of Nigella sativa. Also disclosed are novel processes for the isolation of bioactive components thymohydroquinone, thymoquinone from the seeds of Nigella sativa. A process for the isolation -hederin and hederagenin from the spent material of Nigella sativa is also disclosed herein.

The invention relates to methods for disrupting cholesterol crystals and related methods for the prevention and/or treatment of disease.

The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule -helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.

The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or/and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule -helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.

This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

Disclosed is a method for therapeutic management of hyperglycemia in mammals using compositions containing thymohydroquinone. More specifically, the invention discloses compositions containing thymohydroquinone for inhibiting the activity of the enzyme -glucosidase and increasing the cellular uptake of glucose by mammalian cells. The anti-oxidant, anti-inflammatory and anti-glycation effects of thymohydroquinone are also disclosed herein.